Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Offers $3.5M in Common Stock

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, Transgenomic said it plans to offer up to $3.5 million in common stock for sale on the Nasdaq and other trading markets.

Banking firm Craig-Hallum Capital Group will serve as sales manager, and will receive a commission of 3.25 percent based on the gross sales price, Transgenomic added. The shares will be offered at the prevailing market price.

As of June 6, the company reported its aggregate market value of outstanding common stock held by non-affiliates was $11.2 million based on 22,846,408 shares of outstanding common stock, of which 15,288,240 shares are held by non-affiliates, and a per-share price of $0.73, based on the closing bid price of the common stock as quoted on the Nasdaq on April 20.

Transgenomic's shares were down nearly 7 percent at $.64 in afternoon trading on the Nasdaq.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.